Abstract
Pannexin 3 (Panx3) is a regulator of bone formation. Panx3 forms three distinct functional channels: hemichannels, gap junctions, and endoplasmic reticulum (ER) Ca2+ channels. However, the gating mechanisms of the Panx3 channels remain unclear. Here, we show that the Panx3 ER Ca2+ channel is modulated by phosphorylation of the serine 68 residue (Ser68) to promote osteoblast differentiation. Among the 17 candidate phosphorylation sites identified, the mutation of Ser68 to Ala (Ser68Ala) was sufficient to inhibit Panx3-mediated osteoblast differentiation via reduction of Osterix and ALP expression. Using a Ser68 phospho-specific antibody (P-Panx3) revealed Panx3 was phosphorylated in prehypertrophic, hypertrophic chondrocytes, and bone areas of the newborn growth plate. In osteogenic C2C12 cells, P-Panx3 was located on the ER membranes. Importantly, the Ser68Ala mutation only affected Panx3 ER Ca2+ channel function. Ser68 on Panx3 was phosphorylated by ATP stimulation and PI3K/Akt signaling. Finally, real-time FRET imaging and ratio analysis revealed that the Panx3 channel conformation was sensitive to ATP. Together, the phosphorylation of Panx3 at Ser68 is an essential step controlling the gating of the Panx3 ER Ca2+ channel to promote osteogenesis.
Subject terms: Differentiation, Ion channel signalling, Bone development, Calcium signalling
Introduction
Intracellular Ca2+ signaling regulates cell proliferation, differentiation, morphology, and functions1. Intracellular Ca2+ levels ([Ca2+]i) is controlled by the extracellular space and the ER, a Ca2+ storage organelle. Ca2+ is released from the ER through ER Ca2+ channels located on the ER membrane. These receptors include the inositol-3-trisphosphate (IP3) receptors (IP3Rs) that are ubiquitously expressed2 and the ryanodine receptors (RyRs) expressed in some tissues3. Additionally, pannexins (Panxs), which are members of the gap junction protein family, were recently reported to act as ER Ca2+ channels. The Panx1 ER Ca2+ channel functions in prostate cancer cells4, and Panx3 acts as an ER Ca2+ channel in osteoblasts5.
Gap junctions regulate various intracellular and physiological functions via the exchange of small molecules, such as ATP and ions, from the cell to the extracellular space via hemichannels and from cell to cell via gap junctions6–9. Vertebrates have two gap junction protein families: the connexins (Cxs) and the pannexins (Panxs). The Cxs have more than 20 members and their functions have been reported10. Dysregulations and mutations of Cxs are involved in many human diseases, including cancer, hypertension, atherosclerosis, and developmental abnormalities11. By contrast, Panxs are less well characterized and they consist of only three known members (Panx1–3)12–14. Panx1 is widely expressed, especially in the central nervous system, Panx2 is frequently expressed in the central nervous system15, and Panx3 expression has been reported in the skin, cochlea, and developing hard tissues, including cartilage, bones, and teeth5,16–20. The human disorders linked to the Panxs, and especially Panx1, are associated with ischemia, stroke, overactive bladder, HIV infections, Crohn’s disease, and platelet aggregation21. Further, a germline variant in PANX1 has been associated with dysfunctions that included intellectual disabilities, hearing loss, and other multisystem failures22. Panx3 has been linked to osteoarthritis (OA), a disabling degenerative joint disorder with cartilage destruction, subchondral bone remodeling, and inflammation of the synovial membrane23.
Panx3 is now recognized as a new regulator of bone growth24. Previously, we have identified that Panx3 promotes chondrocyte differentiation by the ATP released via the Panx3 hemichannel, which counteracts the parathyroid hormone (PTH)–related protein (PTHrP) signaling pathway16. We also reported that Panx3 promotes osteoblast differentiation via its functions as a hemichannel, an ER Ca2+ channel, and a gap junction5. In addition, Panx3 regulates the osteoprogenitor cell cycle exit by inhibiting Wnt/β-catenin signaling through its hemichannel25. Panx3-null (Panx3−/−) mice show low bone density and marked dwarfism caused by the failure in both endochondral and intramembranous ossification. An in vivo study showed that Panx3 regulates mature hypertrophic chondrocyte differentiation and is requred in osteogenesis from the early stage, whereas Cx43 plays a role in the maturation stage. We also demonstrated that Panx3 and Cx43 play distinct roles in bone formation26.
Both Cxs and Panxs have common protein structures, including four transmembrane domains, two extracellular loops, one intracellular loop, and N- and C-terminal segments10,27. The tetramer of the subunit forms a channel structure that functions as a hemichannel, gap junction, and ER Ca2+ channel, and the ER Ca2+ channel is Panxs specific. Recently, Panx1 and Panx3 were recognized as N-linked glycosylate proteins. Panx1 has the glycosylation site at asparagine 254 in the second extracellular loop, on the other hand, Panx3 at asparagine 71 in the first extracellular loop28. Panx2 also contains a potential N-linked glycosylation consensus site at asparagine 86, although the glycosylation of this residue has not yet been confirmed. Glycosylation of Panxs plays a role in the appropriate trafficking of these Panxs to the cell surface18,29. However, the mechanisms controling the opening or closing of Panxs, and especially the Panx3 channel, are not yet understood.
In this study, we showed that the Panx3 ER Ca2+ channel is activated by phosphorylation at the Ser68 residue by ATP-mediated PI3K/Akt signaling to promote osteoblast differentiation. Phosphorylation of Panx3 at Ser68 increases intracellular Ca2+ levels through Panx3 ER Ca2+ channel gating, but not via its hemichannel or gap junction functions. Our results reveal that the Panx3 ER Ca2+ channel is regulated by a distinct gating mechanism that differs from the mechanism regulating the hemichannel and gap junction functions.
Results
We analyzed the mechanisms of Panx3 channel gating by first testing whether Panx3 is phosphorylated using Panx3 overexpressing C2C12 cells cultured in osteogenic media by Pro-Q diamond phosphoprotein gel staining30,31, and immunoprecipitation assays (IP). Pro-Q diamond phosphoprotein gel-staining methods were used: total Panx3 protein was immunoprecipitated with V5 antibody, followed by detection of phosphorylation with the Pro-Q gel-staining method. In both Pro-Q staining and IP, total Panx3 protein in immunoprecipitated cell lysate was detected by Western blot using V5 antibody. The amount of total extracted protein (Input) was confirmed with α-tubulin antibody. Cell lysates from the Panx3 overexpressing cells showed a phosphorylated band similar in size to the Panx3 molecular weight, 47 kD, after Pro-Q staining (Fig. 1A,a). The size of the phosphorylated band was dose-dependently decreased by treatment with CIP (ALP) phosphatase (Fig. 1A,a,b). Further, IP with the Panx3 protein showed that the phosphorylated band detected between 45 and 50 kD was recognized by an antibody for serine and threonine phosphorylation. The size of that phosphorylated band was also decreased after CIP treatment (Fig. 1B,a,b). These results suggested that Panx3 is phosphorylated in cultured cells.
We identified specific phosphorylation sites in Panx3 protein by first using a database (NetPhos 2.0 Server) to analyze the candidate sites. We found 17 phosphorylation candidates and made point mutation constructs of each Panx3 phosphorylation candidate site (Fig. 2A). We then used the ALP activity assay as a screen to test which mutation site affected Panx3-mediated osteoblast differentiation. Among the 17 candidate sites, the mutation of the serine 68 (Ser68) and serine 303 (Ser303) residue inhibited the Panx3-mediated promotion of ALP activity (Fig. 2B). Since the mutation of Ser68 revealed the highest inhbition, we then generated a stable cell line of osteogenic C2C12 cells transfected with a phosphorylation of Ser68 mutation (Ser68Ala) vector (Fig. 2C). The cell proliferation rate of the stable Ser68Ala cells was not different from that of the normal Panx3 stably expressed cells (Fig. 2D), whereas the Ser68Ala cells clearly showed reduced Panx3-mediated osterix and ALP expression by qPCR analysis and ALP staining after culturing in osteoinduction medium (Fig. 2E,F). These results indicated that the Ser68 residue of Panx3 was an important site for osteoblast differentiation, but not proliferation.
We generated a phosphorylation-specific antibody to the Ser68 residue of Panx3 (P-Panx3) and tested its specificity with an ELISA assay. The P-Panx3 antibody specifically bound the antigen peptide (P-peptide) (Fig. 3A). We then used the P-Panx3 antibody and western blotting to determine whether Panx3 was phosphorylated in vitro at Ser68. The protein lysate from Panx3 expressing C2C12 cells showed the expected band of P-Panx3 between 45 and 50 kD molecular weight, and the size of that band was diminished by CIP treatment and in cell lysates from Ser68Ala transfected cells (Fig. 3B). These results indicated that the P-Panx3 antibody could detect Panx3 phosphorylation at Ser68. We also clearly detected P-Panx3 in skin, bone, and cartilage tissue from newborn mice by western blotting of molecular weights similar to those in cell culture, but its presence was unclear in brain (Fig. 3C). We immunostained the growth plates of newborn mice to elucidate the site where P-Panx3 was expressed. P-Panx3 was expressed in prehypertrophic and hypertrophic chondrocytes, the perichondrium/periosteum, and the bone area. Interestingly, the intensity of the positive P-Panx3 signal was higher in the prehypertrophic zone than in the proliferative and hypertrophic zones. The immunostaining signal of P-Panx3 disappeared following application of the P-Panx3 antibody mixed with P-peptide (Fig. 3D).
The next question we addressed was how P-Panx3 regulates Panx3 channel functions. We first determined the cellular location of P-Panx3 expression by immunocytochemistry. The merged image obtained with P-Panx3 and ER-tracker or Panx3 revealed that P-Panx3 was expressed strongly on ER membranes, rather than on the plasma membrane or gap junction. Quantitative analysis revealed that 75% of the P-Panx3 protein was colocalized with ER tracker, while no P-Panx3 expression was observed in the Ser68Ala stably transfected C2C12 cells (Fig. 4A,a,b). Further, we also found that P-Panx3 was located on the ER membrane by transmission electron microscopy (TEM) after immunolabeling with P-Panx3 antibody (Fig. 4B). These results suggest that Panx3 is phosphorylated at the Ser68 residue on the ER membrane.
The results of cellular localization of P-Panx3 predicted that Ser68 phosphorylation would play a role in the Panx3 ER Ca2+ channel function. We analyzed Ca2+ efflux from the ER and stimulation of Ca2+ storage by ATP. The Ser68Ala mutation inhibited Panx3-mediated Ca2+ efflux (Fig. 5A). The other functions of Panx3, such as ATP release from the hemichannel and Ca2+ propagation of gap junction activity, were not affected by Ser68Ala (Fig. 5B,C and Supplementary Movie 1–3). Thus, P-Panx3 affects only the ER Ca2+ channel function among the three Panx3 channel functions.
We next examined the regulatory mechanisms of Panx3 ER Ca2+ channel gating by P-Panx3. ATP stimulated the Panx3 ER Ca2+ channel (Fig. 5A), and since we previously reported that the Panx3 ER Ca2+ channel is regulated by the ATP/PI3K/Akt signaling pathway5, we used western blotting to analyze P-Panx3 expression following ATP stimulation. ATP stimulation increased P-Panx3 expression, and this was reversed by CIP treatment and use of the ATP inhibitor, apyrase (Fig. 6A,B). Addition of the Panx3 hemichannel inhibitory peptide (I-peptide) also diminished P-Panx3 expression (Fig. 6B). The PI3K inhibitor, LY294002 also inhibited P-Panx3 (Fig. 6C). The PI3K downstream molecule, Akt constitutive active vector (Akt CA), increased P-Panx3 expression (Fig. 6D). These results suggest that the ATP/PI3K/Akt signaling pathway regulates P-Panx3.
We also examined the Ca2+ signaling pathway in C2C12 cells and in primary calvarial cells transfected with a Ser68Ala vector and induced by BMP2 for 1 h. Ser68Ala inhibited the Panx3-mediated Ca2+ signaling pathway (Fig. 6E,a,b).
We then used fluorescence resonance energy transfer (FRET) analysis to examine the changes in Panx3 protein conformation by phosphorylation to P-Panx3. We created recombinant Panx3 or Ser68Ala with CFP to the N-terminus and YFP to the C-terminus. The FRET real-time imaging of cells co-transfected with CFP and YFP vectors showed that Panx3-expressing C2C12 cells showed FRET after ATP stimulation, while cells treated with apyrase or Ser68Ala expressing cells did not (Fig. 7A and Supplementary Movies 4–6). Quantification of FRET with a luminometer also generated similar results as imaging (Fig. 7B). The FRET analyses indicate that the protein conformation of the Panx3 channel was transformed by ATP-induced phosphorylation at Ser68 to control Panx3 ER Ca2+ channel gating.
Discussion
In this study, we demonstrated that the Panx3 ER Ca2+ channel is regulated by ATP/PI3K/Akt mediated phosphorylation at the Ser68 residue. P-Panx3 has a pronounced involvement in osteoblast differentiation but not in osteoprogenitor proliferation. P-Panx3 is localized on the ER membrane, and mutation of Ser68 inhibits Ca2+ efflux from Panx3 ER Ca2+ channel, but does not affect the ATP releasing hemichannel or the gap junction function, with the end result of propagation of intracellular Ca2+ to neighboring cells. The Panx3 hemichannel releases intracellular ATP to the extracellular space to promote the activation of the PI3K/Akt signaling pathway through purinergic receptors. Panx3 then undergoes phosphorylation at Ser68 on the ER membrane (Fig. 8). The resulting P-Panx3 changes the Panx3 protein conformation to release Ca2+ from ER. These results indicate that the gating of the Panx3 ER Ca2+ channel is regulated by phosphorylation and the gating of each of the three types of Panx3 channels is regulated by different mechanisms.
The Panx3 ER Ca2+ channel is opened by phosphorylation at the Ser68 residue. For the phosphorylation of Panx3 at Ser68, it is possible that Panx3 forms a protein complex with Akt (Fig. 6D). Global Akt-1 KO mice have bone abnormalities that are evident as a reduction in bone mineral density32. The global Akt-2 KO mice develop severe diabetes, and yet they display only a small reduction in weight and length33. Akt-1/Akt-2 double KO mice die shortly after birth and exhibit dwarfism34, while Akt3 KO mice are viable and have reduced brain size, but no apparent mutant skeletal phenotype35. The Panx3 KO mice revealed severe dwarfism and reduction in bone density26. Comparison of the mouse phenotypes between Panx3 KO mice and Akt KO mice suggested that the Panx3 ER Ca2+ channel may be regulated by Akt-1. We still remain unclear how Ser68 of Panx3 at ER membrane can be phosphorylated by a cytoplasmic kinase, Akt. We also were unable to ascertain whether Akt binds Panx3 directly or indirectly. The sequence of the Ser68 site is not the binding consensus sequence for Akt36,37. Thus, one possibility is that the protein complex formed with Akt and other molecules and signaling pathway controlled by them may require to activate the Panx3 ER Ca2+ channel. We need further experiments to answer the question.
Several kinases are reported to bind and activate Akt38–40. One of these, 5′ AMP-activated protein kinase (AMPK) may form a complex with Akt to activate the Panx3 ER Ca2+ channel. We recently found that Panx3 regulates proliferation and differentiation of odontoblasts by AMPK activity through ATP releasing hemichannel activities17. AMPKα1 and AMPKα2 KO mice are viable, but AMPKα1/α2 double KO mice show embryonic lethality41. The AMPKα1 KO mice have severely low bone mass, with both cortical and trabecular bone compartments being smaller42,43. Thus, AMPK could be involved in Panx3 channel regulation. Another potential candidate is BMP2 signaling, because it regulates Panx3 expression and activation of the Panx3 signaling pathway5,25. Thus, BMP2 may contribute to the activation of Panx3 channel. In present study, BMP2 was added for cell culture conditioning in several differentiation experiments. The results suggest that BMP2 may regulate Panx3 channel activation by phosphorylation. BMP2 signaling has two main pathways—smad dependent or independent44. Thus, smad-dependent signaling and an independent pathway, such as MAPK signaling, may interact to cause Panx3 ER Ca2+ channel activation.
Candidate phosphorylation sites other than Ser68 may also exist in Panx3 and may contribute to the regulation of gating of the Panx3 channel, hemichannel, and gap junction by other mechansims. The hemichannel and gap junction are located on the plasma membrane. The gap junction forms between adjacent cells, whereas the hemichannel forms from the cell to the extracellular space. We can therefore expect that the activation mechanisms for each of the hemichannel, gap junction, and ER Ca2+ channel types would differ. In our screening with the ALP assay, we found another interesting site, Ser303 (Fig. 2B). Mutation of Ser303 to Ser303Ala also inhibited Panx3 mediated ALP activity, although the inhibition ratio for Ser303Ala was less than that for Ser68Ala. Ser68Ala inhibited Panx3-mediated osteoblast differentiation, but not proliferation, and inhibited Panx3 ER Ca2+ channel activity (Fig. 2D–F), whereas Ser303Ala inhibited Panx3-mediated osteoblast differentiation and osteoprogenitor cell proliferation (unpublished data). Panx3 inhibits osteoprogenitor cell proliferation by regulating Wnt and p21 signaling25. The inhibition of cell proliferation by Panx3 is regulated by the Panx3 hemichannel activity and the Panx3 hemichannel is the first action channel among the three Panx3 channels. Since Ser303Ala affected cell proliferation, phosphorylation of Ser303 may contribute to Panx3 hemichannel activity strongly. We need further analysis to address this hypothesis.
In terms of gap junction activity, we have not yet identified a candidate phosphorylation site for its control. The directions of the extracellular and intracellular domains of the gap junction should be the same as those of the hemichannel because they are localized on the plasma membrane. However, since gap junction proteins connect to one another inside neighboring cells to form the gap junction, the gating mechanism of gap junction may have different actions from the others. Panxs are also recognized as glycosylation proteins28,29, and glycosylation regulates the trafficking of the Panxs protein to the cell surface and its docking with an adjacent Panxs channel in a neighboring cell to form a gap junction45. Overexpression of N-glycosylation deficient mutants of Panx1 and Panx3 in HeLa cells prevented dye transfer between the cells19. This finding suggests that glycosylation may regulate the contraction of the gap junction. However, the mechanisms controlling Panx3 gap junction activation are still unclear. We cannot ignore the possibility that phosphorylation also may be involved in gap junction gating. Confirmation of this possibility will require further analysis. Our findings suggest that the phosphorylation of Ser68 activates only the Panx3 ER Ca2+ channel activity, not the hemichannel and gap junction activities. These results and the differences in location between each Panx3 channel clearly indicate that each of the three Panx3 channels have their own regulation mechanisms for gating.
Each of the three Panx3 functions orchestrate and harmonize bone formation. Panx3 is induced at the transition stage from cell proliferation to differentiation. Its expression is first induced at the early osteoblast differentiation stage, and it decreases at the mature osteoblast differentiation stage26. The Panx3 expression pattern does not indicate how each channel activates and contributes to the other. In this study, the Panx3 ER Ca2+ channel was phosphorylated by extracellular ATP released from the Panx3 hemichannel following the activation of PI3K/Akt signaling. In the growth plate, P-Panx3 was expressed in the prehypertrophic, hypertrophic zone, and bone areas. The expression level of P-Panx3 was higher in prehypertrophic chondrocytes than in hypertrophic ones, when compared with normal Panx3 expression in the growth plate (Fig. 3D). Most of the P-Panx3 positive cells were not merged with Ocn expressing cells in the bone area, nor was the P-Panx3 expression pattern completely the same as the Panx3 expression pattern. These results suggest that P-Panx3 occurs at an early stage and its level is reduced in the mature stage during development. The transition of cells from a proliferative to a differentiation state would be expected to require a substantial energy flow and huge exchanges of energy. The control of intracellular Ca2+ levels by the Panx3 ER Ca2+ channel predicts that phosphorylation would happen mainly at the transition stage.
The gap junction proteins that are known to regulate bone formation are Panx3 and Cx43. These two proteins have their own distinct functions and expression patterns that function in their contribution to bone growth. Panx3 functions as an ER Ca2+ channel to promote differentiation, and it can rescue mineralization defects in Cx43−/− calvarial cells26, while Cx43 is a phosphorylated gap junction protein46. The cytoplasmic C-terminal domain of Cx43 is important for the formation of gap junction channels46, and its C-terminal domain contains 32 amino acid residues that are phosphorylated by protein kinases47,48, with 15 serine residues phosphorylated by Ca2+/calmodulin protein kinase II (CaMKII)49. Cx43 is also well known as a phospho-substrate for mitogen-activated protein (MAP) kinases, as well as protein kinase C (PKC)50–52. The phosphorylation of Cx43 at the S368 residue reduces hemichannel activity53. Cx43 is also reported to be phosphorylated by Akt to traffic and stabilize the Cx43 protein in the plasma membrane54. Our present findings would allow the addition of a distinct regulation mechanism between Panx3 and Cx43. Although many molecules, including kinases, activate Cx43 channels, Akt works in different systems to control Panx3 and Cx43 channel gating.
In summary, we have shown that the Panx3 ER Ca2+ channel was phosphorylated at Ser68 residue by ATP/PI3K/Akt signaling. This phosphorylation mechanism is critical for promoting osteoblast differentiation. Our results reveal that the three Panx3 channels each have different activation mechanisms and function together to orchestrate osteogenesis.
Materials and Methods
Reagents
A rabbit polyclonal P-Panx3 antibody was raised against a synthetic peptide (amino acid residues, SCFpSPSNFSC) from the first extracellular loop of the mouse Panx3 protein and the native peptide was used as a control sequence (SCFSPSNFSC). Rabbit anti-Panx3 antibody was used as previously described5,16. The Panx3 expression vector (pEF1/Panx3) and the control vector (pEF1) have been described previously16. In brief, the pEF1/Panx3 vector was constructed by cloning the coding sequence of mouse Panx3 cDNA into the pEF1/V5-His vector (Invitrogen). The antibodies were obtained for Ocn from Biomedical Technology; CaMKII and P-CaMKII from Cell Signaling Technology; P-NFATc1 from Santa Cruz Biotechnology, Inc.; V5 from Invitrogen; and NFATc1 from BD. HA was from COVANCE; α-tubulin from Sigma-Aldrich, CIP from New England Biolabs; Apyrase from Sigma-Aldrich; LY294002 from Invitrogen; BMP2 from Humanzyme; and iQ SYBR Green Supermix from Bio-Rad Laboratories. ER-tracker was obtained from Invitrogen. HRP-conjugated goat anti–mouse and goat anti–rabbit IgG were obtained from United States Biological. The Akt-CA was obtained from Addgene. The inhibitory Panx3 peptide was described previously16.
Cell culture
C2C12 cells were grown in DMEM (Invitrogen) containing 10% FBS (HyClone) at 37 °C under 5% CO2. For the experiments, C2C12 cells were induced from osteogenic cells by the addition of 50 µg/ml ascorbic acid (Sigma-Aldrich) and 5 mM β-glycerophosphate (Sigma-Aldrich). For the proliferation assay, the cells (2.5 × 103 cells/ml) were stably transfected with either pEF1/Panx3 or Ser68Ala or control pEF1 and cultured in 96-well plates for 2 days. The cell proliferation activity was evaluated using a cell counting kit (Dojindo). The absorbance was measured using a microplate reader. For osteoblast differentiation, transiently or stably transfected C2C12 cells (∼90% confluence) were cultured in the presence of 300 ng/ml BMP2 (Humanzyme) and 2% FBS. Primary calvarial cells were prepared from the calvaria of newborn mice and cultured in α-minimum essential medium (α-MEM; Invitrogen) with 10% FBS, 100 units/ml of penicillin, and 100 µg/ml of streptomycin, as previously described55. For the experiment with primary calvarial cells, cells were induced by osteogenesis with 50 µg/ml ascorbic acid (Sigma-Aldrich) and 5 mM β-glycerophosphate (Sigma-Aldrich). All experimental procedures were approved by the Animal Care and Use Committee of the National Institute of Dental and Craniofacial Research (protocol no. 15-758) and Tohoku University (protocol no. 2017DnA-035). And all methods were carried out in accordance with relevant laws and legislations of both NIDCR and Tohoku Univeristy.
In vitro phosphatase assay
Protein lysates isolated using PhosphoSafe extraction buffer (EMD Millipore) were run on SDS-PAGE. The phosphorylation band was analyzed by staining with Pro-Q Diamond phosphoprotein gel stain kit (Invitrogen) following the company’s standard protocol. Briefly, immunoprecipitated cell lysate by V5 antibody was loaded into NuPAGE Bis-Tris gels (Thermo). The gel was immersed in a fixed solution (50% methanol and 10% acetic acid) and then incubated at room temperature with gentle shaking for 1 hour. After washing, the gel was stained with Pro-Q Diamond phosphoprotein gel stain, with gentle agitation in the dark for 90 minutes. To reduce the background, the gel then was destained by incubating the gel in a destaining solution (Thermo) with gentle shaking for 30 minutes at room temperature, protected from light. Detaining was repeated several times until the background was reduced.
Enzyme-linked immunosorbent assay (ELISA) and multiplex ELISA
Cytokines were measured by conventional ELISA (R&D Systems, BD, and elisakit.com) or multiplex ELISA (Quansys Biosciences). Both methods were performed as recommended by the manufacturer. If appropriate, cytokine data were normalized to total protein data (Pierce BCA Protein Assay Kit; Thermo Scientific) with the following formula: raw cytokine data (in pg/ml) / total protein concentration in the lysate (in mg/ml).
ALP assay
The phosphorylation sites of interest in Panx3 were screened by constructing a mutation vector of each of 17 phosphorylation candidate residues using a QuikChange XL Site-Directed Mutagenesis Kit (Agilent Technologies). Each mutation construct was transiently transfected into C2C12 cells with Nucleofector (Lonza). The transfected cells were then plated into 96-well culture plates and grown to 100% confluence. The cells were then induced to differentiate into osteoblasts by addition of 300 ng/ml BMP2. The ALP activity was measured in cell layers using a p-nitrophenyl phosphate substrate and an incubation temperature of 37 °C, or it was determined by the tartrate-resistant acid phosphatase (TRACP) & ALP double-stain kit (Takara Bio Inc.). The protein concentration was determined by the BCA protein assay method (Thermo Fisher Scientific).
Immunostaining
For immunostaining of newborn growth plates, the tissues were fixed overnight in paraformaldehyde, embedded in paraffin, and cut into 10-µm sections. After deparaffinization and rehydration, the sections were processed for heat-induced epitope retrieval in pH 6.0 citrate buffer (Dako). The cultured cells were stained by first incubating them in ER-Tracker Red (Invitrogen) for 20 min, followed by fixation in acetone at −20 °C for 2 min. The cells were blocked with Power block (Biocare Medical) and reacted for 2 h at room temperature with primary antibodies. The primary antibodies were detected by Alexa 488 (Invitrogen) or Alexa 594 (Invitrogen) or by Cy-5–conjugated (Jackson ImmunoResearch Laboratories) secondary antibodies. Nuclear staining was performed using Hoechst dye (Sigma-Aldrich). The analysis was performed on an LSM 780 inverted confocal microscope (Carl Zeiss MicroImaging, Inc.).
Immunoelectron microscopy
For immunolocalization of P-Panx3 protein, glutaraldehyde-fixed, Lowicryl-embedded thin sections were first reacted with the primary antibody diluted in PBS with 1% BSA and 0.1% Triton X-100 (1/100 diluted anti-P-Panx3) for 1 h at room temperature. After washing in PBS, grids were incubated for 30 min at room temperature with the goat 1/25 diluted anti-rabbit secondary antibody (Nanoprobes) coupled to 10 nm gold particles diluted in PBS. Following final washing in PBS, the grids were rapidly rinsed in a jet of distilled water, air-dried, and counterstained with 4% uranyl acetate. The sections were analyzed with a Hitachi H7600 transmission electron microscope.
ATP flux
The ATP flux was examined by luminometry, as previously described5,16. C2C12 cells stably expressing pEF1, pEF1/Panx3, or Ser68Ala were seeded at 1.0 × 104 cells/well in a 96-well plate, and cultured for 2 days in DMEM containing 10% FBS. The cells were then washed with PBS, followed by incubation in PBS for 2 min. The supernatant was collected and assayed with luciferase and luciferin (Promega). The luminescence was measured using a Mithras LB 940 multimode plate reader (Berthold).
Measurement of [Ca2+]i and imaging of Ca2+ wave propagation
The [Ca2+]i and imaging of Ca2+ wave propagation were examined as previously described5. The [Ca2+]i measurements were conducted on C2C12 cells stably expressing pEF1, pEF1/Panx3, or Ser68Ala cultured in a 96-well plate for 3 days cultured with DMEM containing 10% FBS and then loaded with 5 µM Fura-2AM (Invitrogen) in Ca2+ containing HBSS for 45 min at 37 °C in 5% CO2. The Ca2+ transients in Ca2+-free HBSS were recorded as the 340/380 nm ratio (R) of the resulting 510 nm emissions determined using a plate reader (TriStar2 LB942; Berthold Technologies). For the stimulation, 200 µM of ATP was automatically injected into the cell cultures by the LB942. The Ca2+ wave propagation was imaged by seeding C2C12 cells stably expressing pEF1, pEF1/Pnax3, or Ser68Ala in a glass-bottomed dish and incubating in Ca2+ containing HBSS containing 4 µM Fluo-4 AM Ca2+ indicator (Invitrogen), 10 µM pluronic F-127 (Invitrogen), 0.1% OxyFluor (Oxyrase), and 2.5 µM caged reagent NP-EGTA AM (Invitrogen) for 30 min at room temperature, followed by washing and incubation with Ca2+-free HBSS. The Ca2+ was uncaged by a two-photon laser set at 730 nm focused on a single cell. The Ca2+ wave propagation was measured at 10 s after the illumination.
Time-lapse FRET imaging and measurement
The plasmids encoding FRET biosensors were constructed by cloning the coding sequence of mouse normal or Ser68 mutated Panx3 cDNA into the pEYFP-N1 and pECFP-C1 vectors (Clontech). C2C12 cells transfected with biosensors were plated on glass-bottomed dishes and cultured with Phenol-Red-free DMEM containing 10% FBS. Time-lapse FRET imaging was performed on a Zeiss LSM 780 confocal microscope (Carl Zeiss MicroImaging, Inc.). The donor and transfer signals were excited by the 458 nm line of an Argon laser and detected simultaneously between 463–509 nm and 519–620 nm. Images were collected from the middle plane of cells. Time-lapse FRET imaging was captured for 30 s after ATP stimulation. To inhibit ATP receptors, the cells were incubated with 20|U Apyrase before capturing the images. To measure FRET ratio, FRET biosensor vectors including normal or Ser68 mutated Panx3 cDNA transiently transfected C2C12 cells were cultured in a 96-well for 2 days. The FRET ratio was recorded as the 485/536 nm ratio using a plate reader (TriStar2 LB942; Berthold Technologies). 200 µM of ATP stimulation was auto-injected by the LB942.
Western blot analysis
The cell lysates were prepared as previously described16. A 10 µg sample of each protein was electrophoresed in 4–12% SDS-polyacrylamide gel (Invitrogen) and transferred onto a polyvinylidene difluoride membrane using an iBlot device (Invitrogen). The membranes were immunoblotted with antibodies using standard protocols.
Data analysis
Each experiment was repeated several times and the data were analyzed using Prism 5 software. Student’s t-tests were used to highlight differences between two groups of data. One-way ANOVA was used for the quantification of band density ratios (Fig. 1A,b), ALP activity (Fig. 2B.F), cell proliferation (Fig. 2D), qPCR data (Fig. 2E), colocalization (Figs. 4A,b and S1B). P < 0.05 was considered statistically significant.
Supplementary information
Acknowledgements
We thank Dr. Masahiro Saito, Hynda Kleinman, and Kenneth Yamada for critical reading. This work was supported in part by the Intramural Research Program of the National Institute of Dental and Craniofacial Research, USA [grant number DE000483-24, -25, and-26 to Y.Y.]; Grants-in-Aid from the Ministry of Education, Science, and Culture of Japan [grant number 16H05514 to M.I. and 26670880 to S.F.]; and the NEXT program [grant number LS010 to S.F.]. M.I. was supported in part by a Research Fellowship from the Japan Society for the Promotion of Science for Young Scientists.
Author contributions
M.I. and Y.Y. designed the experiments. M.I., G.W., P.F., M.I., K.S. and S.F. performed the experiments. R.J.P. provided the FRET vector and helped with the FRET experiments. M.I. wrote the manuscript with input from all the other co-authors.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
is available for this paper at 10.1038/s41598-019-55371-9.
References
- 1.Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol. 2000;1:11–21. doi: 10.1038/35036035. [DOI] [PubMed] [Google Scholar]
- 2.Mikoshiba K. IP3 receptor/Ca2+ channel: from discovery to new signaling concepts. J Neurochem. 2007;102:1426–1446. doi: 10.1111/j.1471-4159.2007.04825.x. [DOI] [PubMed] [Google Scholar]
- 3.Fill M, Copello JA. Ryanodine receptor calcium release channels. Physiol Rev. 2002;82:893–922. doi: 10.1152/physrev.00013.2002. [DOI] [PubMed] [Google Scholar]
- 4.Vanden Abeele F, et al. Functional implications of calcium permeability of the channel formed by pannexin 1. J Cell Biol. 2006;174:535–546. doi: 10.1083/jcb.200601115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ishikawa M, et al. Pannexin 3 functions as an ER Ca(2+) channel, hemichannel, and gap junction to promote osteoblast differentiation. J Cell Biol. 2011;193:1257–1274. doi: 10.1083/jcb.201101050. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Bennett MV, Verselis VK. Biophysics of gap junctions. Semin Cell Biol. 1992;3:29–47. doi: 10.1016/S1043-4682(10)80006-6. [DOI] [PubMed] [Google Scholar]
- 7.Scemes E, Suadicani SO, Dahl G, Spray DC. Connexin and pannexin mediated cell-cell communication. Neuron Glia Biol. 2007;3:199–208. doi: 10.1017/S1740925X08000069. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Bruzzone S, Guida L, Zocchi E, Franco L, De Flora A. Connexin 43 hemi channels mediate Ca2+-regulated transmembrane NAD+ fluxes in intact cells. FASEB J. 2001;15:10–12. doi: 10.1096/fj.00-0566fje. [DOI] [PubMed] [Google Scholar]
- 9.Unger VM, Kumar NM, Gilula NB, Yeager M. Three-dimensional structure of a recombinant gap junction membrane channel. Science. 1999;283:1176–1180. doi: 10.1126/science.283.5405.1176. [DOI] [PubMed] [Google Scholar]
- 10.Evans WH, Martin PE. Gap junctions: structure and function (Review) Mol Membr Biol. 2002;19:121–136. doi: 10.1080/09687680210139839. [DOI] [PubMed] [Google Scholar]
- 11.Laird DW. Life cycle of connexins in health and disease. Biochem J. 2006;394:527–543. doi: 10.1042/BJ20051922. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Baranova A, et al. The mammalian pannexin family is homologous to the invertebrate innexin gap junction proteins. Genomics. 2004;83:706–716. doi: 10.1016/j.ygeno.2003.09.025. [DOI] [PubMed] [Google Scholar]
- 13.D’Hondt C, Ponsaerts R, De Smedt H, Bultynck G, Himpens B. Pannexins, distant relatives of the connexin family with specific cellular functions? Bioessays. 2009;31:953–974. doi: 10.1002/bies.200800236. [DOI] [PubMed] [Google Scholar]
- 14.Panchin Y, et al. A ubiquitous family of putative gap junction molecules. Curr Biol. 2000;10:R473–474. doi: 10.1016/S0960-9822(00)00576-5. [DOI] [PubMed] [Google Scholar]
- 15.Bruzzone R, Hormuzdi SG, Barbe MT, Herb A, Monyer H. Pannexins, a family of gap junction proteins expressed in brain. Proc Natl Acad Sci USA. 2003;100:13644–13649. doi: 10.1073/pnas.2233464100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Iwamoto T, et al. Pannexin 3 regulates intracellular ATP/cAMP levels and promotes chondrocyte differentiation. J Biol Chem. 2010;285:18948–18958. doi: 10.1074/jbc.M110.127027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Iwamoto T, et al. Pannexin 3 regulates proliferation and differentiation of odontoblasts via its hemichannel activities. PLoS One. 2017;12:e0177557. doi: 10.1371/journal.pone.0177557. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Penuela S, et al. Pannexin 1 and pannexin 3 are glycoproteins that exhibit many distinct characteristics from the connexin family of gap junction proteins. Journal of Cell Science. 2007;120:3772–3783. doi: 10.1242/jcs.009514. [DOI] [PubMed] [Google Scholar]
- 19.Penuela S, Celetti SJ, Bhalla R, Shao Q, Laird DW. Diverse subcellular distribution profiles of pannexin 1 and pannexin 3. Cell Commun Adhes. 2008;15:133–142. doi: 10.1080/15419060802014115. [DOI] [PubMed] [Google Scholar]
- 20.Wang XH, Streeter M, Liu YP, Zhao HB. Identification and characterization of pannexin expression in the mammalian cochlea. J Comp Neurol. 2009;512:336–346. doi: 10.1002/cne.21898. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Penuela S, Harland L, Simek J, Laird DW. Pannexin channels and their links to human disease. Biochemical Journal. 2014;461:371–381. doi: 10.1042/Bj20140447. [DOI] [PubMed] [Google Scholar]
- 22.Shao Q, et al. A Germline Variant in the PANX1 Gene Has Reduced Channel Function and Is Associated with Multisystem Dysfunction. Journal of Biological Chemistry. 2016;291:12432–12443. doi: 10.1074/jbc.M116.717934. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Appleton CT, Pitelka V, Henry J, Beier F. Global analyses of gene expression in early experimental osteoarthritis. Arthritis Rheum. 2007;56:1854–1868. doi: 10.1002/art.22711. [DOI] [PubMed] [Google Scholar]
- 24.Ishikawa M, Yamada Y. The Role of Pannexin 3 in Bone Biology. J Dent Res. 2017;96:372–379. doi: 10.1177/0022034516678203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Ishikawa M, Iwamoto T, Fukumoto S, Yamada Y. Pannexin 3 inhibits proliferation of osteoprogenitor cells by regulating Wnt and p21 signaling. J Biol Chem. 2014;289:2839–2851. doi: 10.1074/jbc.M113.523241. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Ishikawa M, et al. Pannexin 3 and connexin 43 modulate skeletal development through their distinct functions and expression patterns. J Cell Sci. 2016;129:1018–1030. doi: 10.1242/jcs.176883. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Penuela S, Gehi R, Laird DW. The biochemistry and function of pannexin channels. Biochim Biophys Acta. 2013;1828:15–22. doi: 10.1016/j.bbamem.2012.01.017. [DOI] [PubMed] [Google Scholar]
- 28.Penuela S, Bhalla R, Nag K, Laird DW. Glycosylation regulates pannexin intermixing and cellular localization. Mol Biol Cell. 2009;20:4313–4323. doi: 10.1091/mbc.E09-01-0067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Boassa D, et al. Pannexin1 channels contain a glycosylation site that targets the hexamer to the plasma membrane. Journal of Biological Chemistry. 2007;282:31733–31743. doi: 10.1074/jbc.M702422200. [DOI] [PubMed] [Google Scholar]
- 30.Agrawal GK, Thelen JJ. A high-resolution two dimensional Gel- and Pro-Q DPS-based proteomics workflow for phosphoprotein identification and quantitative profiling. Methods Mol Biol. 2009;527:3–19, ix. doi: 10.1007/978-1-60327-834-8_1. [DOI] [PubMed] [Google Scholar]
- 31.Nagata-Ohashi K, et al. A pathway of neuregulin-induced activation of cofilin-phosphatase Slingshot and cofilin in lamellipodia. J Cell Biol. 2004;165:465–471. doi: 10.1083/jcb.200401136. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Kawamura N, et al. Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS One. 2007;2:e1058. doi: 10.1371/journal.pone.0001058. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Garofalo RS, et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest. 2003;112:197–208. doi: 10.1172/JCI16885. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Peng XD, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 2003;17:1352–1365. doi: 10.1101/gad.1089403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Easton RM, et al. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol. 2005;25:1869–1878. doi: 10.1128/MCB.25.5.1869-1878.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Obata T, et al. Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J Biol Chem. 2000;275:36108–36115. doi: 10.1074/jbc.M005497200. [DOI] [PubMed] [Google Scholar]
- 37.Ubersax JA, Ferrell JE., Jr. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol. 2007;8:530–541. doi: 10.1038/nrm2203. [DOI] [PubMed] [Google Scholar]
- 38.Hahn-Windgassen A, et al. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem. 2005;280:32081–32089. doi: 10.1074/jbc.M502876200. [DOI] [PubMed] [Google Scholar]
- 39.Mukherjee A, Rotwein P. Akt promotes BMP2-mediated osteoblast differentiation and bone development. J Cell Sci. 2009;122:716–726. doi: 10.1242/jcs.042770. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Yang WL, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science. 2009;325:1134–1138. doi: 10.1126/science.1175065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Um JH, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010;59:554–563. doi: 10.2337/db09-0482. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Shah M, et al. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone. 2010;47:309–319. doi: 10.1016/j.bone.2010.04.596. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Quinn JM, et al. Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function. FASEB J. 2010;24:275–285. doi: 10.1096/fj.09-137158. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Wu M, Chen G, Li YP. TGF-beta and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. 2016;4:16009. doi: 10.1038/boneres.2016.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Boassa D, Qiu F, Dahl G, Sosinsky G. Trafficking dynamics of glycosylated pannexin1 proteins. Cell Communication and Adhesion. 2008;15:119–132. doi: 10.1080/15419060802013885. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.D’Hondt C, et al. Regulation of connexin- and pannexin-based channels by post-translational modifications. Biol Cell. 2013;105:373–398. doi: 10.1111/boc.201200096. [DOI] [PubMed] [Google Scholar]
- 47.Marquez-Rosado L, Solan JL, Dunn CA, Norris RP, Lampe PD. Connexin43 phosphorylation in brain, cardiac, endothelial and epithelial tissues. Biochim Biophys Acta. 2012;1818:1985–1992. doi: 10.1016/j.bbamem.2011.07.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Chen VC, Gouw JW, Naus CC, Foster LJ. Connexin multi-site phosphorylation: mass spectrometry-based proteomics fills the gap. Biochim Biophys Acta. 2013;1828:23–34. doi: 10.1016/j.bbamem.2012.02.028. [DOI] [PubMed] [Google Scholar]
- 49.Huang RY, et al. Identification of CaMKII phosphorylation sites in Connexin43 by high-resolution mass spectrometry. J Proteome Res. 2011;10:1098–1109. doi: 10.1021/pr1008702. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Lampe PD, et al. Phosphorylation of connexin43 on serine368 by protein kinase C regulates gap junctional communication. J Cell Biol. 2000;149:1503–1512. doi: 10.1083/jcb.149.7.1503. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Richards TS, et al. Protein kinase C spatially and temporally regulates gap junctional communication during human wound repair via phosphorylation of connexin43 on serine368. J Cell Biol. 2004;167:555–562. doi: 10.1083/jcb.200404142. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Solan JL, Lampe PD. Connexin43 phosphorylation: structural changes and biological effects. Biochem J. 2009;419:261–272. doi: 10.1042/BJ20082319. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Bao X, Lee SC, Reuss L, Altenberg GA. Change in permeant size selectivity by phosphorylation of connexin 43 gap-junctional hemichannels by PKC. Proc Natl Acad Sci USA. 2007;104:4919–4924. doi: 10.1073/pnas.0603154104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Dunn CA, Su V, Lau AF, Lampe PD. Activation of Akt, not connexin 43 protein ubiquitination, regulates gap junction stability. J Biol Chem. 2012;287:2600–2607. doi: 10.1074/jbc.M111.276261. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Matsunobu T, et al. Critical roles of the TGF-beta type I receptor ALK5 in perichondrial formation and function, cartilage integrity, and osteoblast differentiation during growth plate development. Dev Biol. 2009;332:325–338. doi: 10.1016/j.ydbio.2009.06.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.